What is HC Wainwright’s Estimate for UNCY FY2026 Earnings?

Unicycive Therapeutics, Inc. (NASDAQ:UNCY – Free Report) – Analysts at HC Wainwright lifted their FY2026 earnings per share (EPS) estimates for Unicycive Therapeutics in a note issued to investors on Tuesday, November 17th. HC Wainwright analyst S. Ramakanth now expects that the company will earn ($1.13) per share for the year, up from their previous estimate of ($1.38). HC Wainwright currently has a “Buy” rating and a $13.00 target price on the stock. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($1.14) per share. HC Wainwright also issued estimates for Unicycive Therapeutics’ Q4 2026 earnings at ($0.28) EPS, Q1 2027 earnings at ($0.36) EPS, Q2 2027 earnings at ($0.26) EPS, Q3 2027 earnings at ($0.16) EPS, FY2027 earnings at ($0.71) EPS, FY2028 earnings at $1.83 EPS, FY2029 earnings at $2.28 EPS and FY2030 earnings at $2.59 EPS.

Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) last posted its quarterly earnings results on Monday, November 16th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.10.

A number of other research firms also recently commented on UNCY. Benchmark reaffirmed a “speculative buy” rating and set a $15.00 price objective (up from $13.00) on shares of Unicycive Therapeutics in a report on Thursday, August 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Unicycive Therapeutics in a report on Friday, September 4th. B. Riley Financial reaffirmed a “buy” rating and set a $20.00 price objective (down from $22.00) on shares of Unicycive Therapeutics in a report on Wednesday, August 12th. Wall Street Zen lowered shares of Unicycive Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 14th. Finally, Guggenheim reiterated a “buy” rating and issued a $25.00 price objective (down from $37.00) on shares of Unicycive Therapeutics in a report on Thursday, August 13th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $18.25.

View Our Latest Stock Report on Unicycive Therapeutics

Unicycive Therapeutics Trading Down 3.5%

Shares of UNCY stock opened at $3.57 on Thursday. The company has a market capitalization of $104.19 million, a P/E ratio of -2.14 and a beta of 1.91. Unicycive Therapeutics has a 12 month low of $3.33 and a 12 month high of $8.74. The stock has a 50 day moving average of $4.11 and a two-hundred day moving average of $5.89.

Institutional Investors Weigh In On Unicycive Therapeutics

Institutional investors have recently bought and sold shares of the company. Virtu Financial LLC boosted its position in Unicycive Therapeutics by 412.4% during the 3rd quarter. Virtu Financial LLC now owns 59,484 shares of the company’s stock worth $279,000 after acquiring an additional 47,874 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Unicycive Therapeutics by 80.8% during the 3rd quarter. Goldman Sachs Group Inc. now owns 262,767 shares of the company’s stock worth $1,234,000 after acquiring an additional 117,463 shares in the last quarter. Chicago Partners Investment Group LLC raised its holdings in shares of Unicycive Therapeutics by 26.0% in the third quarter. Chicago Partners Investment Group LLC now owns 26,966 shares of the company’s stock valued at $105,000 after purchasing an additional 5,556 shares during the last quarter. Pinnacle Wealth Planning Services Inc. acquired a new stake in shares of Unicycive Therapeutics in the third quarter valued at approximately $36,000. Finally, Seven Fleet Capital Management LP raised its holdings in shares of Unicycive Therapeutics by 85.6% in the second quarter. Seven Fleet Capital Management LP now owns 103,400 shares of the company’s stock valued at $521,000 after purchasing an additional 47,700 shares during the last quarter. Institutional investors own 40.42% of the company’s stock.

Top Unicycive Therapeutics Stories

These are some of the UNCY stories that stood out recently:

  • Positive Sentiment: HC Wainwright raised its estimates for several periods, including FY2026 EPS to ($1.13) from ($1.38) and FY2027 to ($0.71) from ($0.86), while maintaining a Buy rating and $13 price target. The improved estimates could support sentiment. MarketBeat
  • Neutral Sentiment: Brookline Capital Markets issued markedly more optimistic long-range forecasts, projecting positive EPS from FY2027 onward. These are analyst projections and differ substantially from HC Wainwright’s outlook, so they add uncertainty rather than a clear consensus signal. MarketBeat
  • Negative Sentiment: Noble Financial lowered its FY2026 EPS estimate to ($0.80) from ($0.62), including a deeper projected Q4 loss. HC Wainwright also cut its FY2028–FY2030 EPS forecasts substantially, although it retained its Buy rating and $13 target; these longer-term reductions may weigh on investor expectations. MarketBeat

About Unicycive Therapeutics

(Get Free Report)

Unicycive Therapeutics is a biopharmaceutical company focused on developing treatments for kidney diseases. Its lead program, oxylanthanum carbonate (OLC), is an oral phosphate binder being developed to help manage hyperphosphatemia, or elevated blood phosphate levels, in people with chronic kidney disease, including patients receiving dialysis. The company is also developing UNI-494, an investigational small-molecule therapy for acute kidney injury. These programs reflect Unicycive’s focus on conditions for which treatment options may be limited.

Read More

Earnings History and Estimates for Unicycive Therapeutics (NASDAQ:UNCY)

Receive News & Ratings for Unicycive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unicycive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.